211 related articles for article (PubMed ID: 35021603)
21. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA
Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907
[TBL] [Abstract][Full Text] [Related]
22. Tyrosine kinase 2 (TYK2) in cytokine signalling and host immunity.
Strobl B; Stoiber D; Sexl V; Mueller M
Front Biosci (Landmark Ed); 2011 Jun; 16(9):3214-32. PubMed ID: 21622231
[TBL] [Abstract][Full Text] [Related]
23. Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway.
Lonetti A; Cappellini A; Bertaina A; Locatelli F; Pession A; Buontempo F; Evangelisti C; Evangelisti C; Orsini E; Zambonin L; Neri LM; Martelli AM; Chiarini F
J Hematol Oncol; 2016 Oct; 9(1):114. PubMed ID: 27776559
[TBL] [Abstract][Full Text] [Related]
24. Targeting the Tyrosine Kinase 2 (TYK2) Pseudokinase Domain: Discovery of the Selective TYK2 Inhibitor ABBV-712.
Breinlinger E; Van Epps S; Friedman M; Argiriadi M; Chien E; Chhor G; Cowart M; Dunstan T; Graff C; Hardee D; Herold JM; Little A; McCarthy R; Parmentier J; Perham M; Qiu W; Schrimpf M; Vargo T; Webster MP; Wu F; Bennett D; Edmunds J
J Med Chem; 2023 Oct; 66(20):14335-14356. PubMed ID: 37823891
[TBL] [Abstract][Full Text] [Related]
25. Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels.
Bressanin D; Evangelisti C; Ricci F; Tabellini G; Chiarini F; Tazzari PL; Melchionda F; Buontempo F; Pagliaro P; Pession A; McCubrey JA; Martelli AM
Oncotarget; 2012 Aug; 3(8):811-23. PubMed ID: 22885370
[TBL] [Abstract][Full Text] [Related]
26. Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition.
Lupardus PJ; Ultsch M; Wallweber H; Bir Kohli P; Johnson AR; Eigenbrot C
Proc Natl Acad Sci U S A; 2014 Jun; 111(22):8025-30. PubMed ID: 24843152
[TBL] [Abstract][Full Text] [Related]
27. Tyrosine Kinase 2-mediated Signal Transduction in T Lymphocytes Is Blocked by Pharmacological Stabilization of Its Pseudokinase Domain.
Tokarski JS; Zupa-Fernandez A; Tredup JA; Pike K; Chang C; Xie D; Cheng L; Pedicord D; Muckelbauer J; Johnson SR; Wu S; Edavettal SC; Hong Y; Witmer MR; Elkin LL; Blat Y; Pitts WJ; Weinstein DS; Burke JR
J Biol Chem; 2015 Apr; 290(17):11061-74. PubMed ID: 25762719
[TBL] [Abstract][Full Text] [Related]
28. Comparative efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and network meta-analysis.
Han Y; Wang J; Wang Z; Xu B
Curr Probl Cancer; 2020 Dec; 44(6):100606. PubMed ID: 32446638
[TBL] [Abstract][Full Text] [Related]
29. The dual specificity PI3K/mTOR inhibitor PKI-587 displays efficacy against T-cell acute lymphoblastic leukemia (T-ALL).
Gazi M; Moharram SA; Marhäll A; Kazi JU
Cancer Lett; 2017 Apr; 392():9-16. PubMed ID: 28159681
[TBL] [Abstract][Full Text] [Related]
30. Targeting Wnt/β-catenin and PI3K/Akt/mTOR pathways in T-cell acute lymphoblastic leukemia.
Evangelisti C; Chiarini F; Cappellini A; Paganelli F; Fini M; Santi S; Martelli AM; Neri LM; Evangelisti C
J Cell Physiol; 2020 Jun; 235(6):5413-5428. PubMed ID: 31904116
[TBL] [Abstract][Full Text] [Related]
31. Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235.
Hall CP; Reynolds CP; Kang MH
Clin Cancer Res; 2016 Feb; 22(3):621-32. PubMed ID: 26080839
[TBL] [Abstract][Full Text] [Related]
32. Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia.
Tasian SK; Teachey DT; Li Y; Shen F; Harvey RC; Chen IM; Ryan T; Vincent TL; Willman CL; Perl AE; Hunger SP; Loh ML; Carroll M; Grupp SA
Blood; 2017 Jan; 129(2):177-187. PubMed ID: 27777238
[TBL] [Abstract][Full Text] [Related]
33. The depletion of Circ-PRKDC enhances autophagy and apoptosis in T-cell acute lymphoblastic leukemia via microRNA-653-5p/Reelin mediation of the PI3K/AKT/mTOR signaling pathway.
Ling Z; Fang ZG; Wu JY; Liu JJ
Kaohsiung J Med Sci; 2021 May; 37(5):392-401. PubMed ID: 33615686
[TBL] [Abstract][Full Text] [Related]
34. A novel requirement for Janus kinases as mediators of drug resistance induced by fibroblast growth factor-2 in human cancer cells.
Carmo CR; Lyons-Lewis J; Seckl MJ; Costa-Pereira AP
PLoS One; 2011; 6(5):e19861. PubMed ID: 21625473
[TBL] [Abstract][Full Text] [Related]
35. Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.
Pikman Y; Alexe G; Roti G; Conway AS; Furman A; Lee ES; Place AE; Kim S; Saran C; Modiste R; Weinstock DM; Harris M; Kung AL; Silverman LB; Stegmaier K
Clin Cancer Res; 2017 Feb; 23(4):1012-1024. PubMed ID: 28151717
[No Abstract] [Full Text] [Related]
36. A novel recurrent NPM1-TYK2 gene fusion in cutaneous CD30-positive lymphoproliferative disorders.
Velusamy T; Kiel MJ; Sahasrabuddhe AA; Rolland D; Dixon CA; Bailey NG; Betz BL; Brown NA; Hristov AC; Wilcox RA; Miranda RN; Medeiros LJ; Jeon YK; Inamdar KV; Lim MS; Elenitoba-Johnson KS
Blood; 2014 Dec; 124(25):3768-71. PubMed ID: 25349176
[TBL] [Abstract][Full Text] [Related]
37. JAK kinases overexpression promotes in vitro cell transformation.
Knoops L; Hornakova T; Royer Y; Constantinescu SN; Renauld JC
Oncogene; 2008 Mar; 27(11):1511-9. PubMed ID: 17873904
[TBL] [Abstract][Full Text] [Related]
38. Discovering what makes STAT signaling TYK in T-ALL.
Fontan L; Melnick A
Cancer Discov; 2013 May; 3(5):494-6. PubMed ID: 23658297
[TBL] [Abstract][Full Text] [Related]
39. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells.
Gao N; Flynn DC; Zhang Z; Zhong XS; Walker V; Liu KJ; Shi X; Jiang BH
Am J Physiol Cell Physiol; 2004 Aug; 287(2):C281-91. PubMed ID: 15028555
[TBL] [Abstract][Full Text] [Related]
40. Intracellular reactive oxygen species are essential for PI3K/Akt/mTOR-dependent IL-7-mediated viability of T-cell acute lymphoblastic leukemia cells.
Silva A; Gírio A; Cebola I; Santos CI; Antunes F; Barata JT
Leukemia; 2011 Jun; 25(6):960-7. PubMed ID: 21455214
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]